Alnylam Pharmaceuticals
ALNY
$320.53
Share price
-1.28%
Change (1 day)
34.77%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Earnings for Alnylam Pharmaceuticals (ALNY)
Earnings in 2025 (TTM): -$0.22 Billion USD
According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are $2.34 Billion USD. In 2024 the company made an earning of -$0.24 Billion USD, an increase over its 2023 earnings that were of -$0.32 Billion USD. The earnings displayed on this page is the company's Pretax Income.
Earnings history for Alnylam Pharmaceuticals from 2003 to 2025
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2025 (TTM)  | -$0.22 Billion | -10.78% |
| 2024 | -$0.24 Billion | -24.59% |
| 2023 | -$0.32 Billion | -67.84% |
| 2022 | -$0.98 Billion | 36.93% |
| 2021 | -$0.71 Billion | -8.04% |
| 2020 | -$0.78 Billion | -15.66% |
| 2019 | -$0.92 Billion | 12.23% |
| 2018 | -$0.82 Billion | 62.91% |
| 2017 | -$0.51 Billion | 17.78% |
| 2016 | -$0.43 Billion | 43.44% |
| 2015 | -$0.3 Billion | 60.69% |
| 2014 | -$0.19 Billion | 98.2% |
| 2013 | -$92.95 Million | |
| 2011 | -$54.82 Million | 27.48% |
| 2010 | -$43.01 Million | -10.92% |
| 2009 | -$48.28 Million | 95.77% |
| 2008 | -$24.66 Million | |
| 2006 | -$39.51 Million | -9.13% |
| 2005 | -$43.48 Million | 34.74% |
| 2004 | -$32.27 Million | 36.79% |
| 2003 | -$23.59 Million |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Arrowhead Pharmaceuticals
ARWR | -$89.25 Million | -57.53% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | $4.98 B | -2,471.93% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | -$0.17 Billion | -21.86% | 🇺🇸 USA |
 OPKO Health
OPK | -$0.56 Million | -99.74% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | -$47.43 Million | -77.43% | 🇺🇸 USA |
 Novartis NVS | $14.91 B | -7,199.31% | 🇨🇭 Switzerland |
 Sanofi SNY | $8.76 B | -4,273.11% | 🇫🇷 France |
 Teva Pharmaceutical Industries TEVA | $0.45 B | -316.05% | 🇮🇱 Israel |